Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Fish and Richardson
Chubb
Healthtrust
Farmers Insurance
Daiichi Sankyo
Cerilliant
Dow

Generated: August 14, 2018

DrugPatentWatch Database Preview

GADOFOSVESET TRISODIUM - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for gadofosveset trisodium and what is the scope of gadofosveset trisodium patent protection?

Gadofosveset trisodium is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gadofosveset trisodium has forty-three patent family members in twenty-six countries.

Summary for GADOFOSVESET TRISODIUM
International Patents:43
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 2
Clinical Trials: 6
Formulation / Manufacturing:see details
DailyMed Link:GADOFOSVESET TRISODIUM at DailyMed
Synonyms for GADOFOSVESET TRISODIUM
193901-90-5
211570-55-7
9430ZR8ZAN
Ablavar (TN)
D04286
DB06705
Gadofosveset trisodium (USAN)
Gadolinate(3-), (((4R)-4-(bis((carboxy-kappaO)methyl)amino-kappaN)-6,9-bis((carboxy-kappaO)methyl)-1-((4,4-diphenylcyclohexyl)oxy)-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-oic acid-kappaN6,kappaN9,kappaO11) 1-oxidato(6-)
Gadolinate(3-), ((4-(bis((carboxy-kappaO)methyl)amino-kappaN)-6,9-bis((carboxy-kappaO)methyl)-1-((4,4-diphenylcyclohexyl)oxy)-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-oic acid- kappaN6, kappaN9, kappaO11) 1-oxidato(6-))-
gadolinium(3+) tripotassium 2-{[1-({2-[bis(carboxylatomethyl)amino]ethyl}(carboxylatomethyl)amino)-3-[(4,4-diphenylcyclohexyl phosphonato)oxy]propan-2-yl](carboxylatomethyl)amino}acetate hydrate
HSDB 8232
MS 325
Trisodium (N-(2-(bis(carboxymethyl)amino)ethyl)-N-((R)-2-(bis(carboxymethyl)amino)-3-hydroxypropyl)glycine 4,4-diphenylcyclohexyl hydrogen phosphato (6-))gadolinate(3-)
UNII-9430ZR8ZAN
Vasovist

US Patents and Regulatory Information for GADOFOSVESET TRISODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for GADOFOSVESET TRISODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for GADOFOSVESET TRISODIUM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,815 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
7,060,250 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
7,229,606 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
8,017,105 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
8,394,356 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for GADOFOSVESET TRISODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007003 Lithuania ➤ Sign Up PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
C0028 France ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
C 037/2006 Ireland ➤ Sign Up SPC 037/2006: 20070528, EXPIRES: 20201002
0806968/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
2007003,C0806968 Lithuania ➤ Sign Up PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
0253 Netherlands ➤ Sign Up 300253, 20160116, EXPIRES: 20201002
2007 00016 Denmark ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Merck
McKinsey
US Army
Harvard Business School
Citi
Teva
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.